Selective laser trabeculoplasty versus medication for open-angle glaucoma: systematic review and meta-analysis of randomised clinical trials

• Published in: British journal of ophthalmology Vol. 104; no. 11; pp. 1500 - 1507
• Main Authors: Chi, Sheng Chu, Kang, Yi-No, Hwang, De-Kuang, Liu, Catherine Jui-ling
• Format: Journal Article
• Language: English
• Published: England BMJ Publishing Group LTD 01.11.2020
• Subjects: Aged; Antihypertensive Agents - therapeutic use; Bias; Clinical medicine; Clinical trials; Female; Glaucoma; Glaucoma, Open-Angle - drug therapy; Glaucoma, Open-Angle - physiopathology; Glaucoma, Open-Angle - surgery; Glaucoma, Open-Angle - therapy; Humans; Hypertension; Intraocular Pressure - physiology; Laser Therapy - methods; Lasers; Lasers, Solid-State - therapeutic use; Male; Meta-analysis; Quality Assurance, Health Care; Quality of life; Randomized Controlled Trials as Topic; Systematic review; Tonometry, Ocular; Trabecular Meshwork - surgery; Trabeculectomy - methods; treatment lasers; glaucoma
• ISSN: 0007-1161; 1468-2079
• DOI: 10.1136/bjophthalmol-2019-315613

BackgroundThe only widely accepted, effective treatment for open-angle glaucoma (OAG) is to reduce the intraocular pressure (IOP), with medical therapy being the typical first-line therapy. Notably, an alternative therapy is selective laser trabeculoplasty (SLT), which is safe and effective in lowering the IOP. Nonetheless, whether SLT could replace medication as the first-line therapy for OAG is still under debate.MethodsStudies involving randomised controlled trials conducted before August 2019 that compared the efficacy of SLT-related and medication-only treatments for OAG were selected from PubMed, Embase, Cochrane Library and Web of Science. Grading of Recommendations, Assessment, Development and Evaluations (GRADE) methodology was employed to rate the quality of the body of evidence.Results1229 patients in eight trials were included. The overall results revealed no significant differences between SLT-related and medication-only treatments regarding the IOP reduction (mean difference (MD): 0.18, 95% CI −0.72 to 1.07, p=0.70, I2=73%) and the success rate of IOP control (risk ratio: 1.02, 95% CI 0.99 to 1.04, p=0.74, I2=0%). The SLT-related therapy group required significantly fewer medications compared with the medication-only group (MD: −1.06, 95% CI −1.16 to −0.96, p<0.0000, I2=5%). A quantitative analysis was not performed concerning adverse events and quality of life because of the limited data available.ConclusionSLT is safe and has a lower incidence of ocular side effects. SLT can be the choice of first-line therapy for OAG. However, clinicians should consider the cost-effectiveness, as well as the patient’s characteristics, before deciding on the therapeutic option.